KENNEWICK, Wash., Jan. 25, 2007 (PRIME NEWSWIRE) -- Advanced Medical Isotopes Corporation's (Pink Sheets:ADMD) Chief Executive Officer, William Stokes, is pleased to announce the licensing of United States Patent 6,680,993. Stokes said, "This patent is involved with the methods and processes directed to the preparation of Actinium-225 and daughters having high radiochemical and radionuclidic purity, which may be used for the preparation of radiopharmaceuticals for linkage to therapeutics such as those containing monoclonal antibodies, proteins, peptides, antisense, statin, natural products and hormones. Most importantly, the alpha-emitting radionuclide Actinium-225 and daughters can be used for both therapeutic and diagnostic purposes."
Alpha-emitting radionuclides, combined with monoclonal antibodies target specific cancer cells. Once injected into the body, the drugs travel throughout the bloodstream until they move into and/or lock onto the targeted cells. Most importantly, these high-energy alpha particles do not significantly damage healthy surrounding tissue, resulting in very low side effects. Memorial Sloan-Kettering Cancer Center studies have shown positive results with acute myeloid leukemia, breast, ovarian, lymphoma, neuroblastoma and prostrate cancers. Actinium-225 and the isotope Bismuth-213, the radioactive decay product of Actinium-225, are supplied in limited quantities globally and hindered utilization.
Chairman of the company's Scientific Advisory Board, Dr. Robert E. Schenter, Ph. D., added, " Advanced Medical Isotopes Corporation is planning to commence production in the upcoming months of a multitude of rare and valuable medical isotopes such as Actinium-225 to assist with the diagnosis and treatment of major diseases such as cancer, heart disease, and arthritis."
About Advanced Medical Isotopes Corporation ("ADMD")
ADMD is engaged in the development of manufacturing equipment and new techniques for the local production of advanced medical isotopes used in the diagnosis and treatment of disease. The field of nuclear medicine has routinely utilized radioisotopes in the diagnosis of disease while new processes are being pioneered for the targeted treatment of diseases such as cancer in preference to surgical techniques. Advanced Medical Isotopes Corporation products will support the accessibility to these less invasive therapeutic processes by advancing systems for lower-cost production and improving supply availability of medical isotopes to hospitals and treatment centers.
Forward-Looking Statements
Except for historical information contained herein, the matters set forth in this press release, such as statements relating the company's ability to drive technological developments and the acceptance and timing of product introductions, are forward-looking statements that are subject to risks and uncertainties, including but not limited to, timely development and acceptance of new products, the impact of competitive products and pricing, the timely development and release of products by suppliers, and other risks.